Drugs / AK137
last change Dec 2024 re-read 3 minutes ago

AK137

Developed for
cancer
Investigated by
Akeso

Trials 1

202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06691360 Dec 2024 → May 2027 expected cancer Akeso Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AK137 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06691360 ↗
Route Intravenous “IV infusion” NCT06691360 ↗